Optimi Health Corp. OPTH PHARMA
Company Overview
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.
Why Investors Should Care
Revenue has grown at a 74.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.29.
Recent Developments
- Sep 2025 Revenue of $426.30K (+9.4% YoY); net profit $-3.71M.
- Trailing 12 Months Year-on-year growth — revenue -28.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 74.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 74.15% |
| 1 Year: | -28.60% |
Stock Price Performance
| 1 Year: | -20.39% |
| 6 Months: | - |
| 3 Months: | -6.20% |
| 1 Month: | -4.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)49.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 74.2% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OPTH Optimi Health Corp. PHARMA | 4.84 | -3.36 | $27.71M | 0.00% | -68.54% | -54.36% | 74.15% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 61.24K | 196.39K | -64.03K | 0 | 99.50K |
| Cost of Revenue | - | 17.30K | 14.46K | 400.20K | 0 | 10.04K |
| Gross Profit | - | 43.94K | 181.93K | -464.23K | 0 | 89.46K |
| Operating Expenses | - | 1.03M | 979.71K | 1.20M | 1.28M | 1.45M |
| Operating Income | - | -989.05K | -797.78K | -1.67M | -1.28M | -1.36M |
| EBITDA | - | 139.18K | -570.97K | -876.15K | -1.01M | -1.13M |
| Interest Expense | - | 111.44K | 109.74K | 202.49K | 278.79K | 236.77K |
| Pretax Income | - | -196.37K | -907.32K | -1.35M | -1.55M | -1.59M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -196.37K | -907.32K | -1.35M | -1.55M | -1.59M |
| Diluted EPS | -0.30 | -0.06 | -0.30 | - | -0.60 | -0.49 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 80.72K | 181.09K | 389.85K | 426.30K |
| Cost of Revenue | - | 26.80K | -19.14K | 118.94K | 494.43K |
| Gross Profit | - | 53.92K | 200.23K | 270.91K | -68.13K |
| Operating Expenses | - | 7.44M | 5.47M | 5.88M | 4.54M |
| Operating Income | - | -7.39M | -5.27M | -5.61M | -4.61M |
| EBITDA | - | -7.03M | -4.42M | -4.74M | -2.23M |
| Interest Expense | - | 27.99K | 43.71K | 429.34K | 531.68K |
| Pretax Income | - | -7.35M | -5.19M | -6.04M | -3.71M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -7.35M | -5.19M | -6.04M | -3.71M |
| Diluted EPS | - | -2.70 | -1.80 | -2.10 | -1.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 16.82M | 16.49M | 14.55M | 15.21M |
| Current Assets | - | 2.43M | 2.43M | 1.23M | 1.83M |
| Cash & Equivalents | - | 1.89M | 1.34M | 103.66K | 1.15M |
| Inventory | - | 264.72K | 779.27K | 894.82K | 310.39K |
| Receivables | - | 98.70K | 165.74K | 124.15K | 95.05K |
| Total Liabilities | - | 797.66K | 3.28M | 4.98M | 8.64M |
| Current Liabilities | - | 728.18K | 1.61M | 3.22M | 8.48M |
| Long Term Debt | - | - | 1.64M | 1.76M | - |
| Total Debt | - | 157.58K | 1.71M | 2.75M | 6.52M |
| Total Equity | - | 16.02M | 13.21M | 9.58M | 6.57M |
| Shares Outstanding | - | 2.70M | 2.90M | 3.16M | 3.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.58M | -3.60M | -4.28M | -2.63M |
| Investing Cash Flow | - | -3.15M | -706.02K | -154.02K | -88.38K |
| Financing Cash Flow | - | 1.19M | 3.76M | 3.19M | 3.76M |
| Capital Expenditure | - | -7.15M | -804.23K | -152.39K | -88.38K |
| Free Cash Flow | - | -11.73M | -4.41M | -4.43M | -2.72M |
| Net Change in Cash | - | -6.54M | -543.80K | -1.24M | 1.04M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 66.8% | 110.6% | 69.5% | -16.0% |
| Operating Margin % | - | -9,155.2% | -2,911.5% | -1,438.8% | -1,081.9% |
| Net Margin % | - | -9,106.9% | -2,868.5% | -1,548.3% | -870.8% |
| ROE % | - | -45.9% | -39.3% | -63.0% | -56.5% |
| ROCE % | - | -45.9% | -35.4% | -49.5% | -68.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LP | 3.48% | 199.00K | $985.05K |
| 2 | Mariner, LLC | 2.14% | 122.25K | $605.14K |
| 3 | AdvisorShares Investments, LLC | 1.80% | 102.79K | $508.83K |
| 4 | Two Sigma Securities, LLC | 0.19% | 10.59K | $52.44K |
| 5 | UBS Group AG | 0.10% | 5.87K | $29.07K |
| 6 | Royal Bank of Canada | 0.03% | 1.96K | $9.72K |
| 7 | TD Waterhouse Canada Inc. | 0.01% | 333 | $1.65K |
| 8 | National Bank of Canada/FI/ | 0.01% | 598 | $2.96K |
| 9 | Arax Advisory Partners | - | 50 | $247 |
| 10 | Northwestern Mutual Wealth Management Company | - | 136 | $673 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OPTH
Psychedelic-drug maker Optimi Health (OPTH) plans investor meetings in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxONnV0OHVCemZSYVNvTF9KcnZNaWpUMFpxbjVTTnlqVlJEZFVfcExlazR6LTM5OEFJOTZhaEdzdzYtZ2xfR3NiQlp6T2ZEX3JudlJNd2w5TnNHa1lCeVJ0dGpTeVc3UjRjNlRCQUxUUTNlTUxVTlkzWFBiVWNmOGkwMzd3QjNWTlNIMHhrNj…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE8zMDVxYUNScVNzMUM1Z01IMTVtazRUVk40czRkcUxNd21KVks3bXlUUF9JazlldmNIelp5RFA4T0xJVTQyQWtGSGd4YzRubjkw?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Optimi Health Corp. Common Shares (NASDAQ: OPTH) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFBFLVF1TzUwWmdSR1BXOHQ4N2g0ZE1UUVlqYTV3Q2VlenQ5cUM1V0xZbVI3WmgwdEoyLUx3OWxrV180STZOTUxtWUtqYlJYc2lkV3FURkln?oc=5" target="_blank">Optimi Health Corp. Common Shares (NASDAQ: OPTH) St…
What is the current Price Target and Forecast for Optimi Health Corp. (OPTH) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9sOXpDZFlna3JaWWg5N3BlMkplQk1BR1FsZ21fcDVoOTVJT2dFV3NLLXBCN3Y1RDBIbUtKVFZnanV2cml1eWNfWkJwbjQzZFdDWFgzVC03VmVlMFdoNUhfT3pjU016NzZ5aDU0T0V6Wk1ycnJtSk9vOA?oc=5" target="_blank">What …
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOUHpDbi1vSmxIX2dmN2l2bnI2dVU3a1pHSzAwS3c4cjR3b0NIWHRrdFRDR0Vvb0JiNHh1UXVGWU1MSUxFWGlocm9xSE5wRngtWDdReTFnemhmNTVZT0JlMDgtaFpCZ0tWQ2lhZ0d0NnpIOVlTTjVPU08yTHJ6OUQtQjJpUDJHUkRqQ2dyRz…
Optimi Health (OPTH) Stock Price, News & Analysis - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE9BT055dFRuR19RSTQtc3hnOFJDVTF0dEVJRThNQmJCTUozcVhyekpWdHZVM3hhc1Vnem55X0pXd1hxVEt6SlFhTG9WRzd2elMyN3dxZnpWMlJOZw?oc=5" target="_blank">Optimi Health (OPTH) Stock Price, News & Anal…
OPTH — Frequently Asked Questions
What is the current share price of Optimi Health Corp. (OPTH)?
As of 2026-09-19 21:16 PDT, Optimi Health Corp. (OPTH) trades at $4.84 on NasdaqCM. Its 52-week range is $4.01 to $6.08.
What is the market capitalisation of OPTH?
Optimi Health Corp. (OPTH) has a market capitalisation of $27.71M on NasdaqCM.
What is the P/E ratio of OPTH?
OPTH trades at a trailing price-to-earnings (P/E) ratio of -3.36. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.22.
What is the return on equity (ROE) of OPTH?
OPTH has a return on equity (ROE) of -54.36%. Its return on capital employed (ROCE) is -68.54%.
Is OPTH a good stock to buy?
This page provides a data-driven analysis of Optimi Health Corp. (OPTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.